Novavax’s Updated COVID-19 Vaccine Receives Emergency Use Authorization in the Republic of Korea – Nov 29, 2023 – Novavax Investor Relations

Novavaxs partner, SK bioscience,today announced that Novavaxs updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization from the Ministry of Food and Drug Safety in the Republic of Korea.Doses are available in market for use this vaccination season.InSouth Korea, SK bioscience and Novavax have a licensing agreement where SK bioscience has exclusive commercial rights to Novavaxs updated COVID-19 vaccine.

Read more:

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in the Republic of Korea - Nov 29, 2023 - Novavax Investor Relations

Related Posts
Tags: